Background: A previous study in type 2 diabetic patients with high-normal body lead burdens showed that EDTA chelation therapy for 3 months slows progressive diabetic nephropathy during a 12-month follow-up. The effect of a longer course of therapy on kidney function decrease over a longer follow-up is not known.
nvironmental exposure to lead, indicated by blood lead level, is thought to influence kidney function in healthy individuals. 1, 2 Because blood lead level indicates only recent exposure to lead, 3, 4 x-ray fluorescence methods and EDTA mobilization tests have been used to analyze body lead burden. Urinary lead excretion Ͻ600 g/72 h after EDTA chelation therapy is considered to represent a normal body lead burden, whereas excretion of 80-600 g/72 h is considered high-normal. Previous studies of nondiabetic patients with chronic kidney disease and normal body lead burdens [5] [6] [7] [8] [9] have suggested that environmental exposure to lead accelerates progressive decreases in kidney function and that repeated chelation therapy may retard disease progression in patients with highnormal body lead burdens.
During the past quarter century, the prevalence of type 2 diabetes has nearly doubled in the United States and has increased 3-to 5-fold worldwide. 10 Diabetes currently is the major cause of end-stage renal disease in both developed and emerging nations. 11, 12 Previous studies have shown that bone lead content 13 or body lead burden, 14 assessed by EDTA mobilization tests, is associated with progressive loss of kidney function in diabetic patients. Moreover, a clinical trial indicated that EDTA chelation therapy retards progressive diabetic nephropathy in type 2 diabetic patients with high-normal body lead burdens.
14 However, the sample size of the trial was small (N ϭ 30 patients), the duration of the trial was short (3 months of treatment with a 12-month followup), and estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) Study equation 15 rather than the Chinese equation, 16 which is a modified formula for calculating eGFR in Chinese patients. Hence, the role of EDTA chelation therapy in retarding diabetic nephropathy remains debatable. Because current treatments for diabetic nephropathy are of limited efficacy, 17 more effective treatment options are urgently required. Therefore, in the present study, we conducted a clinical trial in type 2 diabetic patients with high-normal body lead burden to determine whether a longer course of EDTA chelation therapy delays the progression of diabetic nephropathy during a 2-year period.
METHODS

Participants
The study protocol was approved by the Medical Ethics Committee of the Chang Gung Memorial Hospital (Taipei, Taiwan). Patients aged 30-83 years who had type 2 diabetes mellitus and received follow-up care at the Chang Gung Memorial Hospital for at least 1 year were eligible for inclusion in this study. Patients were recruited from the Nephrology Outpatient Department, and all patients with diabetic nephropathy were screened; a total of 86 individuals completed this 12-month run-in period.
Inclusion criteria for the randomized trial were as follows: serum creatinine concentration of 1.5-3.9 mg/dL, urinary protein excretion Ͼ0.5 g/d, diabetic retinopathy with laser therapy, pathologic diagnosis of diabetic nephropathy, absence of microhematuria, echograms showing normal-sized kidneys, history of diabetes for more than 5 years, no known history of exposure to lead or other heavy metals, and body lead burden of 80-600 g, determined by the EDTA mobilization test in 72-hour urine samples.
Exclusion criteria were as follows: type 1 diabetes; decreased kidney function because of a potentially reversible cause, such as malignant hypertension, urinary tract infection, hypercalcemia, or drug-induced nephrotoxic effects; presence of other systemic diseases, such as connective-tissue diseases; use of drugs that might alter the course of the kidney disease, for example, nonsteroidal anti-inflammatory agents, steroids, immunosuppressive drugs, or Chinese herbal drugs; any drug allergy; and absence of a signed informed consent form.
The blood pressure of each patient was maintained at Ͻ140/90 mm Hg by administering diuretics and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, with or without calcium-blocking agents and/or vasodilators. Patients with systolic blood pressure Ͻ100 mm Hg were not administered angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Calcium carbonate was used to maintain patient phosphate levels. Because they had normal intact parathyroid hormone levels (Ͻ200 pg/mL), no patient was administered vitamin D 3 supplements or erythropoietin. All patients received dietary consultations and were recommended to follow a diabetic diet (35 kcal per kilogram of body weight per day) with normal protein intake (0.8-1.0 g of high-biological-value protein per kilogram of body weight per day). A nutritionist reviewed the dietary intake of each patient every 3-6 months. The 24-hour urea excretion levels were analyzed every 3 months to determine patient adherence to dietary recommendations.
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Measurement of Creatinine
Serum and urine creatinine levels in patients were determined by the alkaline picrate method of Jaffé 19 using an autoanalyzer (Hitachi 7600; Hitachi, www.hitachi.com). Bio-Rad Lyphochek control (Bio-Rad, www.bio-rad.com) was used as the creatinine reference standard to determine intrabatch accuracy and ensure interbatch standardization of the creatinine assay. The coefficient of variation for creatinine measurement was 2.6% at 1.4 mg/dL. External quality control was maintained by participation in the College of American Pathologists' Survey Program 3 times every year for 3 years. Both internal and external quality control procedures achieved consistently satisfactory results.
Measurement of Blood Lead Level and Body Lead Burden
Blood lead level and body lead burden were measured at the end of the run-in phase using a previously described method. [4] [5] [6] [7] [8] [9] Body lead burden was measured using the EDTA mobilization test, modified by Behringer et al. 20 Urinary excretion was pooled over 72 hours after intravenous infusion of 1 g of calcium disodium EDTA (edetate calcium disodium [calcium disodium versenate]; Abbott Laboratories, www.abbott.com). Blood and urine lead levels were determined using electrothermal atomic-absorption spectrometry (SpectrAA-200Z; Agilent Technologies, www.agilent. com) with Zeeman background correction and L'vov platform. Both internal and external quality control procedures were applied throughout this study, and satisfactory results were consistently achieved. We used a certified and commercially manufactured product (Seronorm Trace Elements; Sero AS, www.sero.no) to monitor intrabatch accuracy and ensure interbatch standardization. The coefficient of variation for lead measurement was Ͻ5.3%. External quality control was maintained by participating in the governmental National Quality-Control Program.
Study Protocol
This study consisted of a 12-month run-in phase followed by a randomized single-blind study with a 27-month intervention and follow-up between August 2007 and October 2009.
The 12-Month Run-in Period
Serum creatinine, glycosylated hemoglobin (HbA 1c ), daily urine protein excretion, daily protein intake, mean arterial pressure, and serum high-and low-density lipoprotein cholesterol levels were measured using an autoanalyzer system (model 736; Hitachi). These measurements were performed at the beginning and end and every 3 months during the 12-month run-in period. Patient blood pressure and body mass index also were measured at 3-month intervals. We collected laboratory data and 2 consecutive 24-hour urine samples from each patient and recorded the mean value of the 2 measurements. In the case of patients for whom urine collection data were incomplete (Ͼ1 missed urine collection) or who had inadequate urine flow (Ͻ1 mL/min), another urine 
The 27-Month Intervention Period
The 12-month run-in period was followed by a 27-month, single-blind, randomized, placebo-controlled study. On the basis of previous studies, [4] [5] [6] [7] [8] [9] we defined high-normal body lead burden as a minimum of 80 g of lead (0.39 mol) and a maximum of 600 g (2.90 mol). We randomly assigned 50 patients with high-normal body lead burden and serum creatinine level Յ3.9 mg/dL (Յ353.6 mol/L) to a control or treatment group. During the first 3 months, treatment-group patients received weekly 2-hour intravenous infusions of 1 vial (1 g) of calcium disodium EDTA mixed with 200 mL of normal saline solution until body lead burden was Ͻ60 g (Ͻ0.29 mol), whereas control patients received weekly 2-hour infusions of 1 vial (20 mL) of 50% glucose mixed with 200 mL of normal saline solution over 5 weeks. 9 Treatment-group patients were administered repeated lead chelation therapy if their serum creatinine levels exceeded prechelation baseline levels in the first 3 months and body lead burden was Ͼ60 g or if body lead burden was Ͼ60 g at their regular body lead burden reassessments every 6 months during the intervention period. Control patients were administered placebo weekly for 5 weeks every 6 months during the intervention period. In order to record possible changes in patient kidney function, laboratory measurements were conducted at 3-month intervals for an additional 24 months after the initial placebo or EDTA chelation therapy.
Outcome Measures
Temporal changes in kidney function (assessed by eGFR) of patients during the study period were considered to be the primary end point. An increase in serum creatinine level to 2-fold that of baseline level or need for renal replacement therapy was considered to be the secondary end point. As an analysis of the sensitivity of the primary end point measure, we included all patients in the analysis and assumed that those on renal replacement therapy had eGFR of 5 mL/min/1.73 m 2 .
Sample Size Calculation
To detect mean differences between the treatment and control groups in rate of change in eGFR of 1.7 Ϯ 0.6 (SD) mL/min/1.73 m 2 at 3-month intervals, which is in agreement with our previous study, 14 with a 2-sided 5% significance level and power Ͼ80%, the standard deviations of eGFR in the treatment and control groups ranging from 4.43-7.54 and 6.15-9.21 mL/min/1.73 m 2 , respectively, and the expected variability (ie, standard deviation) within participants of 3.86 mL/min/1.73 m 2 , a sample size of 18 patients per group was necessary, given an anticipated dropout rate of 20%. To recruit this number of patients, we anticipated needing a 12-month run-in period.
Statistical Analysis
Differences between groups were assessed using t tests for continuous variables and 2 tests for categorical variables. MannWhitney U test was used to assess variables without normal distribution. Differences in rates of progression of decreased kidney function between the 2 groups were analyzed using t tests and Mann-Whitney U tests. All P values were 2 tailed, and all results were presented as mean Ϯ standard deviation values. Univariate analysis using Cox regression was performed to assess the effect of baseline variables on the secondary outcome. Variables with P Ͻ 0.05 in univariate analysis were entered into the Cox regression multivariable analysis for further evaluation. Data were presented as the hazard ratio (HR) with 95% confidence interval (CI). The cumulative percentage of all patients who reached the secondary end point was measured using the Kaplan-Meier method and log-rank test. P Ͻ 0.05 was considered to be statistically significant.
RESULTS
Run-in Period (Months 0-12)
A total of 86 patients completed the 12-month run-in phase, and body lead burden was measured at the end of this period. Sixty-five of these had highnormal body lead burdens (Ն80-Ͻ600 g), and after excluding those with serum creatinine level greater than the inclusion threshold and those who did not supply written informed consent, 50 patients (40 men and 10 women) who met the inclusion criteria participated in the clinical trial (Fig 1) . In the 12-month run-in period prior to randomization, the yearly rate of decrease in eGFR in those later assigned to the treatment group was 10. 
Intervention Period (Months 0-27)
Initial Chelation Therapy (Months 0-3) Both groups had similar baseline characteristics (Table 1) . After the 3 months of lead chelation therapy, the body lead burden of treatment-group patients decreased to 49.9 Ϯ 18.7 (range, 9.2-68.0) g, and blood lead levels decreased to 3.4 Ϯ 1.9 (range, 1.3-9.1) g/dL. The average therapeutic dose of calcium disodium EDTA was 5.6 Ϯ 2.6 (range, 3-12) g. After the initial chelation therapy, an improvement in kidney function of treatment-group patients was observed (Table 2 ; change in eGFR, ϩ1.0 Ϯ 4.8 mL/min/ 1.73 m 2 in the treatment group vs Ϫ1.5 Ϯ 4.8 mL/min/ 1.73 m 2 in the control group; P ϭ 0.04).
Repeated Chelation Therapy (Months 4-27)
The 2 groups did not differ in terms of body mass index; mean arterial pressure; levels of serum HbA 1c , high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol; daily urinary protein excretion; or daily protein intake (Table 3) throughout the intervention period. During this period, 5 patients in the treatment group required Note: A high-normal body lead burden was defined as lead level of at least 80 g (0.39 mol), but Ͻ600 g (Ͻ2.9 mol). Values for continuous variables given as mean Ϯ standard deviation (range); values for categorical variables given as number (percentage). Conversion factors for units: serum creatinine in mg/dL to mol/L, ϫ88.4; cholesterol in mg/dL to mmol/L, ϫ0.02586; lead in g/dL to mol/L, ϫ0.04286.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor antagonists; CCB, calcium channel blocker; CCr, creatinine clearance rate; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a P values were calculated by 2 test, except in the comparisons of age, body mass index, serum creatinine, CCr, GFR, blood lead level, and body lead burden, which were calculated by t test.
b Hyperlipidemia was defined as serum cholesterol level Ͼ240 mg/dL (Ͼ6.2 mmol/L) after diet control. c Hypertension was defined by the presence of at least 2 blood pressure measurements Ն140/90 mm Hg in a patient who was receiving antihypertensive drugs.
d Previous cardiovascular disease included ischemic heart disease, congestive heart failure, peripheral vascular disease, and cerebrovascular disease. e eGFR calculated by the formula for Chinese with type 2 diabetes.
only one course of repeated chelation therapy, whereas 8 required 2 courses, 10 required 3 courses, and 2 required 4 courses. The mean dose of calcium disodium EDTA administered to patients during repeated chelation therapy was 5.2 Ϯ 2.7 (range, 3-9) g. At the end of this study, blood lead level (3.8 Ϯ 1.2 g/dL) and body lead burden (46.0 Ϯ 23.1 g) of treatment-group patients were lower than blood lead level (6.8 Ϯ 3.1 g/dL; P ϭ 0.03) and body lead burden (151.3 Ϯ 93.6 g; P Ͻ 0.001) of control patients. At this stage, the eGFR of treatment-group patients (17.4 Ϯ 11.4 mL/min/1.73 m 2 ) was higher than that of the control group (9.7 Ϯ 6.7 mL/min/1.73 m 2 ; P ϭ 0.006; Table 2 ). The yearly rate of decrease in eGFR of the treatment group during this period was 5.6 Ϯ 5.0 mL/min/1.73 m 2 , which was less than that of the control group (9.2 Ϯ 3.6 mL/min/1.73 m 2 ; P ϭ 0.04; Table 2 ; Fig 2) . No side effects of repeated lead chelation therapy were observed during the 27-month study period. Twenty-six patients, including 17 (68%) control-group patients and 9 (36%) treatment-group patients, reached the secondary end point during the study period (P ϭ 0.02, log-rank test; Fig 3) . Of these 26 patients who showed a 2-fold increase in baseline serum levels, 11 (44%) control-group patients and 4 (16%) treatment-group patients received renal replacement therapy.
As a sensitivity test, if an eGFR of 5 mL/min/1.73 m 2 was assumed for kidney function in patients with renal replacement therapy, similar results were obtained. At the end of the clinical trial, the eGFR of treatment-group patients (16.0 Ϯ 11.4 mL/min/1.73 m 2 ) was higher than that of the control group (8.3 Ϯ 6.0 mL/min/1.73 m 2 ; P Ͻ 0.001). The yearly rate of decrease in eGFR in the treatment group during this period was 6.4 Ϯ 5.0 mL/min/1.73 m 2 , which was less than that of the control group (9.8 Ϯ 3.2 mL/min/1.73 m 2 , P ϭ 0.02). Multivariable Cox analysis showed that EDTA treatment reduced the risk (HR, 0.39; 95% CI, 0.16-0.93; P ϭ 0.03) of the secondary outcome during the 27-month study period (Table 4) . [4] [5] [6] [7] [8] [9] 14, 21, 22 the data we present here show that EDTA therapy may delay the progression of diabetic nephropathy. In the present study, we enrolled a new cohort that was not included in our previous studies.
14 There also were several differences from our previous studies that allowed us to make a number of new observations and draw more definitive conclusions about the effects of EDTA treatment in retarding the progression of diabetic nephropathy. First, the present study differed from our previous studies with respect to the definition of the secondary end point (serum creatinine level 2-fold vs 1.5-fold that of baseline), follow-up period (27 vs 15 months), sample size (50 vs 30 participants), and treatment method (repeated EDTA treatment vs no treatment during the follow-up period). Second, multivariable Cox analysis shows that EDTA chelation therapy results in a 61% decrease in risk of achieving the secondary outcome. Third, although our sample size was small (N ϭ 50), we found that statistical power was Ͼ0.80. However, because we had included only patients with a high-normal body lead burden in this study and hence had only a small sample size, we could not show that body lead burden predicts changes in kidney function. The mechanism by which EDTA chelation therapy retards progressive diabetic nephropathy is unclear. However, plasma nitric oxide (NO) levels are increased after EDTA administration and there is greater and more diffuse endothelial NO synthase expression in kidneys of rats treated with EDTA than in control animals. 23 In addition, EDTA administration prevents tumor necrosis factor ␣-induced renal vascular leakage and protects rat kidneys from ischemic damage in vivo, potentially by stimulation of NO production. 23 EDTA chelation therapy also can remove contaminating metals and decrease free radical production. 24, 25 This therapy exerts long-term antioxidant effects because plasma peroxide levels in patients have been observed to decrease persistently. 25 Moreover, repeated EDTA chelation therapy protects cellular lipids against oxidative damage. 25, 26 Lead chelation reduces levels of reactive oxygen species, enhances the availability of NO to vascular smooth muscle cells, and decreases blood pressure in rats with lead-induced hypertension. 27 Hence, improvements in kidney function in our patients after EDTA treatment may be due to the antioxidative effects of the therapy in addition to the removal of lead.
The EDTA chelating agent, administered at smaller doses and over longer intervals, has been used safely to treat patients with chronic kidney disease. [5] [6] [7] [8] [9] 14, 21, [28] [29] [30] The mean dose of EDTA used in the present study was only 5.6 g in the initial 3 months and 5.2 g in the 24-month follow-up. This dosage is much lower than that used for treating patients with acute lead poisoning, who are administered 40-60 g of EDTA within 2-3 weeks. Some researchers argue that lead redistribution resulting from EDTA chelation therapy may increase concentrations of lead in the brain, thereby causing brain damage. However, animal studies 24, 31 have not shown an increase in brain lead concentrations after EDTA chelation therapy. Stangle et al 32 showed that 2,3-dimercaptosuccinic acid chelation impairs cognitive ability in 30-day-old rats without lead exposure. However, the dose of chelating agent in that study was as large as that used to treat acute poisoning and was given over a short period (3 weeks). Therefore, it is not surprising that the chelating agent may have induced cognitive impairment in these very young animals.
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One of the limitations of the present study was the use of eGFR to assess kidney function. However, studies by Leung et al 16 of eGFR in Chinese patients with type 2 diabetes showed a strong correlation between eGFR and GFR measured by an isotopic method (r 2 ϭ 0.95). Another limitation was that body lead burden was assessed using the EDTA mobilization test. Lead that can be chelated predominantly reflects lead concentrations in blood, soft tissues, and a fraction of the trabecular bone, but not cortical bone. 33 Because kidneys are included in soft tissues, EDTA mobilization may reflect lead content of the kidney, 24 which may influence progressive chronic kidney disease. Measurements of bone lead with x-ray fluorescence methods may be more useful to assess body lead burden than the EDTA mobilization test. However, there are several important limitations to measurements of bone lead concentrations by x-ray fluorescence methods, 33 such as lack of precision, nonhomogenous lead distribution in cortical bone, and a low turnover rate with low biological activity of lead in cortical bone. Glucose may interfere with the Jaffé method to measure creatinine. 34 Although HbA 1c levels were similar between the control and treatment groups in the present study, the use of methods 35 to improve specificity and minimize susceptibility to interfering substances is required in future studies. Another limitation of our study was that it had an incomplete single-blind placebo design and there may have been unrecognized differences in care, such as antihypertensive drug treatment and dietary counseling, between the 2 assigned treatment groups. However, no differences in blood pressure, HbA 1c levels, or blood lipid levels were noted between the 2 treatment groups during the course of the study. Because ϳ70% of patients with diabetic nephropathy have been found to have a high-normal body lead burden (80-600 g) in a previous (61/87; 70.1%) and the present study (65/86; 75.6%), the results we present here might be generalizable to the larger diabetic nephropathy population.
In conclusion, our study results indicate that when other treatable factors are controlled, EDTA chelation treatment may delay the rapid progression of diabetic nephropathy in type 2 diabetic patients with highnormal body lead burdens. Our results may be important because diabetic nephropathy is a major global cause of end-stage renal disease. 
